Marshall & Sullivan Inc. WA lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,701 shares of the medical research company’s stock after selling 161 shares during the quarter. Thermo Fisher Scientific comprises 2.6% of Marshall & Sullivan Inc. WA’s investment portfolio, making the stock its 19th biggest position. Marshall & Sullivan Inc. WA’s holdings in Thermo Fisher Scientific were worth $3,730,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in shares of Thermo Fisher Scientific by 0.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,706,326 shares of the medical research company’s stock worth $605,651,000 after acquiring an additional 17,860 shares during the period. Meeder Asset Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 73.2% in the 1st quarter. Meeder Asset Management Inc. now owns 1,237 shares of the medical research company’s stock worth $338,000 after acquiring an additional 523 shares during the period. Pennsylvania Trust Co lifted its stake in shares of Thermo Fisher Scientific by 38.1% in the 1st quarter. Pennsylvania Trust Co now owns 58,862 shares of the medical research company’s stock worth $16,112,000 after acquiring an additional 16,246 shares during the period. Baxter Bros Inc. lifted its stake in shares of Thermo Fisher Scientific by 2.2% in the 1st quarter. Baxter Bros Inc. now owns 29,600 shares of the medical research company’s stock worth $8,102,000 after acquiring an additional 630 shares during the period. Finally, Winslow Evans & Crocker Inc. lifted its stake in shares of Thermo Fisher Scientific by 2.8% in the 1st quarter. Winslow Evans & Crocker Inc. now owns 17,298 shares of the medical research company’s stock worth $4,736,000 after acquiring an additional 470 shares during the period. 89.24% of the stock is owned by institutional investors and hedge funds.

In other news, Director C Martin Harris sold 275 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total transaction of $74,450.75. Following the sale, the director now owns 6,433 shares in the company, valued at $1,741,606.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total transaction of $14,241,500.00. Following the sale, the chief executive officer now owns 342,193 shares in the company, valued at approximately $97,466,832.19. The disclosure for this sale can be found here. Insiders sold a total of 52,775 shares of company stock worth $14,986,676 over the last quarter. Insiders own 0.45% of the company’s stock.

Shares of NYSE TMO traded up $2.78 during midday trading on Wednesday, reaching $278.97. The company’s stock had a trading volume of 26,404 shares, compared to its average volume of 1,574,825. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58. The company has a 50 day moving average price of $285.71 and a 200 day moving average price of $272.38. Thermo Fisher Scientific Inc. has a one year low of $208.34 and a one year high of $305.45. The company has a market cap of $110.59 billion, a price-to-earnings ratio of 25.09, a price-to-earnings-growth ratio of 1.81 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, topping analysts’ consensus estimates of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The business had revenue of $6.32 billion for the quarter, compared to the consensus estimate of $6.31 billion. During the same period in the previous year, the firm earned $2.75 EPS. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.24 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, September 17th will be issued a $0.19 dividend. The ex-dividend date of this dividend is Monday, September 16th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is currently 6.83%.

A number of brokerages have recently weighed in on TMO. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research note on Thursday, May 30th. They issued an “outperform” rating for the company. Argus upped their price target on shares of Thermo Fisher Scientific from $285.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. BTIG Research upped their price target on shares of Thermo Fisher Scientific to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Credit Suisse Group reaffirmed a “buy” rating and issued a $310.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Finally, Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price target for the company in a research note on Wednesday, June 12th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus price target of $303.17.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: How to build a Fibonacci channel

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.